Artelo Biosciences Reports Third Quarter 2023 Financial Results and Provides Business Update
November 13, 2023 08:00 ET
|
Artelo Biosciences
$12.9 Million in Cash and Investments as of September 30, 2023;Runway Expected to Reach Meaningful Development Milestones On Track to Submit IND Application with the FDA for ART26.12 During the First...
Artelo Biosciences Announces Publication of New Peer-Reviewed Research Demonstrating Protective Properties of ART27.13 Against Muscle Degeneration Caused by Certain Cancers
November 09, 2023 09:00 ET
|
Artelo Biosciences
SOLANA BEACH, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop...
Artelo Biosciences to Present Preclinical Data Showcasing Research on ART26.12 and ART12.11 in Anxiety and Depression at Neuroscience 2023
November 02, 2023 08:30 ET
|
Artelo Biosciences
SOLANA BEACH, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop...
Principal Investigator of Artelo’s CAReS Trial to Participate in Medical Expert Webinar Hosted by H.C. Wainwright to Discuss Current Development Strategies for Cancer-Related Anorexia and Cachexia
October 04, 2023 08:30 ET
|
Artelo Biosciences
SOLANA BEACH, Calif., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop...
Artelo Biosciences to Present at the 13th Congress of the European Pain Federation on September 20th
September 13, 2023 08:30 ET
|
Artelo Biosciences
SOLANA BEACH, Calif., Sept. 13, 2023 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop...
Artelo Biosciences Completes Positive Pre-IND Meeting with FDA for ART26.12
September 07, 2023 08:00 ET
|
Artelo Biosciences
SOLANA BEACH, Calif., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop...
Artelo Biosciences to Present at the 6th Cannabinoid-Derived Drug Development Summit on September 12th
September 06, 2023 09:00 ET
|
Artelo Biosciences
SOLANA BEACH, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop...
Artelo Biosciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference on September 13th
September 05, 2023 09:00 ET
|
Artelo Biosciences
SOLANA BEACH, Calif., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop...
Artelo Biosciences Reports Second Quarter 2023 Financial Results and Provides Business Update
August 10, 2023 08:00 ET
|
Artelo Biosciences
SOLANA BEACH, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop...
Artelo Biosciences to Present New Mechanism of Action Data on ART26.12 at the Gordon Research Conference on July 20, 2023
July 19, 2023 09:00 ET
|
Artelo Biosciences
SOLANA BEACH, Calif., July 19, 2023 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop...